Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Abstract Objectives Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method Pooled data from Phase 2 (NCT01786668; 04/2013–03/2015)/Phase 3 (NCT03502616; 06/2018–08/2020) RCTs in AS patients were analyzed (3...

詳細記述

書誌詳細

主要な著者:	Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel El-Zorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranic, Sujatha Menon, Dona L. Fleishaker, Annette M. Diehl, Lara Fallon, Arne Yndestad, Robert B. M. Landewé
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2024-12-01
シリーズ:	Advances in Rheumatology
主題:	Janus kinase inhibitors/adverse effects Spondylitis Ankylosing Tofacitinib
オンライン･アクセス:	https://doi.org/10.1186/s42358-024-00402-x
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!